RxDoctor Payments Data

Thomas Rumble, MD

Psychiatry · Dublin, GANPI 1306823323

Payments from drug & device makers

$2,359in general payments, 2019–2025

Across 133 payments — averaging $17.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$955
  • Teva Pharmaceuticals USA, Inc.$358
  • Neurocrine Biosciences, Inc.$255
  • Alkermes, Inc.$197
  • Sunovion Pharmaceuticals Inc.$154
  • Otsuka America Pharmaceutical, Inc.$129
  • plus $310 from 7 others

What the payments were for

  • Food & beverage$2,14291%
  • Education$2179%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,359 in reported general payments places this provider in the 75th percentile of 900 psychiatry providers in Georgia.

See all psychiatry providers in Georgia

Medicare billing

Part B allowed, 2024
$7,720
Medicare patients
34
Services billed
84

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate35$273,525
Invega SustennaPaliperidone Palmitate64$225,234
VraylarCariprazine Hcl13$18,093
Divalproex Sodium ErDivalproex Sodium72$3,593
Clozapine58$3,067
Quetiapine Fumarate140$2,873
Haloperidol66$2,676
Ziprasidone Hcl38$2,674
Paliperidone ErPaliperidone32$2,484
Haloperidol Decanoate44$2,373
Aripiprazole106$2,177
Clonazepam230$1,986
Oxcarbazepine37$1,593
Methylphenidate ErMethylphenidate Hcl15$1,457
Trazodone Hcl158$1,444

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$255$273,52535 claims
Johnson & JohnsonInvega Sustenna$955$225,23464 claims
AbbVieVraylar$89$18,09313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 900 psychiatry providers in Georgia.

Other psychiatry in Dublin

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →